Using PET/MR imaging for advanced nasopharyngeal cancer
PET/MR in Locally Advanced Nasopharyngeal Carcinoma
This study is testing if a new type of imaging called PET/MR can help doctors better understand and plan treatment for patients with advanced nasopharyngeal cancer.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | N/A to 70 Years |
| Sex | All |
| Sponsor | Zhejiang Cancer Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Trial ID | NCT03657017 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the use of PET/MR imaging technology in patients with locally advanced nasopharyngeal carcinoma. The study aims to evaluate the effectiveness of this imaging technique in staging and treatment planning for patients with newly diagnosed non-keratinizing carcinoma. Participants will undergo PET/MR scans to assess tumor characteristics and guide therapeutic decisions. The trial includes specific eligibility criteria to ensure that participants have appropriate health status and cancer staging.
Who should consider this trial
Good fit: Ideal candidates are patients with newly histologically confirmed non-keratinizing nasopharyngeal carcinoma who meet specific health criteria.
Not a fit: Patients with adenocarcinoma or those over the age of 70 may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve the accuracy of diagnosis and treatment planning for patients with nasopharyngeal carcinoma.
How similar studies have performed: While the use of PET/MR imaging is gaining traction, this specific application in nasopharyngeal carcinoma is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with newly histologically confirmed non-keratinizing carcinoma. * Tumor staged T1-4N0-3M0 （according to the 8th AJCC staging system） * Performance status: KPS\>70 * With normal liver function test (ALT, AST \<1.5ULN) * Renal: creatinine clearance \>60ml/min * Without hematopathy,marrow: WBC \>4\*109/L, HGB\>80G/L, and PLT\>100\*109/L. * Written informed consent Exclusion Criteria: * Adenocarcinoma * Age \>70 * Prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) * Previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended RT treatment volume) * Patient is pregnant or lactating * Any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×ULN), or emotional disturbance.
Where this trial is running
Hangzhou, Zhejiang
- Xiaozhong Chen — Hangzhou, Zhejiang, China (Recruiting)
Study contacts
- Study coordinator: Caineng Cao, MD
- Email: caocaineng777@sina.com
- Phone: 0571-88128202
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.